Anixa Biosciences
Quarterly Financials
| Values in thousands | 2026-04-30 | 2026-01-31 | 2025-10-31 | 2025-07-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -10 | -9 | -9 | |
EBITDA | -2,536 | -2,575 | -2,749 | -2,271 |
EBIT | -2,585 | -2,722 | -2,280 | |
Net Income | -2,556 | -2,565 | -2,695 | -2,258 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -1,741 | -2,610 | -1,255 | -1,511 |
Cash | 1,477 | 1,547 | 1,244 | 1,495 |
Basic Shares | 33,593 | 33,240 | 32,454 | 32,476 |
Annual Financials
| Values in thousands | 2025-10-31 | 2024-10-31 | 2023-10-31 | 2022-10-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $210 | $2,469,000 |
Gross Profit | -36 | -37 | 49 | 2,468,958 |
EBITDA | -10,992 | -12,661 | -9,884 | -13,729 |
EBIT | -11,028 | -12,698 | -9,930 | -13,771 |
Net Income | -10,927 | -12,554 | -9,811 | -13,595 |
Net Change In Cash | 0 | 0 | 210 | 2,469,000 |
Cost of Revenue | -16,768 | |||
Free Cash Flow | -7,173 | -7,335 | -6,209 | -6,492 |
Cash | 1,244 | 1,271 | 915 | 12,360 |
Basic Shares | 32,454 | 31,898 | 30,980 | 30,374 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-04-30 | -$0.07 |
2026-01-31 | -$0.08 |
2025-10-31 | -$0.08 |
2025-07-31 | -$0.07 |